In Quest To Transform Biotech, Moderna Secures $110M To Get Into Clinic
This article was originally published in The Pink Sheet Daily
This biotech envisions a day when messenger RNA therapeutics enable a patient’s body to produce needed proteins in vivo, thereby vastly expanding the universe of druggable targets and bypassing all of the patented large-molecule drugs that are the industry’s foundation.
You may also be interested in...
Armed with cash from a robust M&A and a stock market boom, mutual and hedge funds are eagerly crossing over into mezzanine rounds for private biotechs and playing key roles in some of the year’s biggest venture financings.
While public, regulatory and law enforcement attitudes toward marijuana in the U.S. continue to shift, it’s still tough to pursue legitimate clinical research on cannabis and cannabinoids. Could the exceptions slowly become the rule?
An estimated 400 million people globally are infected with hepatitis B, which can result in liver cancer and cirrhosis. Recent advances in RNA and other technologies may provide movement toward a cure, but it’s not clear yet if the biopharma industry will find the economics motivating enough for an all-out effort.